Research Topics
Genomes and Genes | Philip J BarterSummaryAffiliation: The Heart Research Institute Country: Australia Publications
| Collaborators
|
Detail Information
Publications
Effect of high-density lipoproteins on the expression of adhesion molecules in endothelial cellsPhilip J Barter
Lipid Research Laboratory, Hanson Institute for Medical Research, Adelaide, Australia
Curr Opin Lipidol 13:285-8. 2002..The mechanism of this potentially anti-atherogenic effect of HDLs remains uncertain, as does its contribution to the cardioprotective effects of HDLs in vivo...- Cardioprotective properties of fibrates: which fibrate, which patients, what mechanism?Philip J Barter
Circulation 113:1553-5. 2006 - Relationship between the concentration and antiatherogenic activity of high-density lipoproteinsPhilip J Barter
The Heart Research Institute, Sydney, Australia
Curr Opin Lipidol 17:399-403. 2006..The relationship between the concentration of high-density lipoprotein cholesterol and their protective function is addressed... - Homocysteine and cardiovascular disease: is HDL the link?Philip J Barter
Circ Res 99:565-6. 2006 
Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatmentGilles Lambert
The Heart Research Institute, Sydney, Australia
Clin Chem 54:1038-45. 2008..Proprotein convertase subtilisin/kexin type 9 (PCSK9) promotes the degradation of the LDL receptor (LDLr) in hepatocytes, and its expression in mouse liver has been shown to decrease with fenofibrate treatment...- The inflammation: lipoprotein cyclePhilip Barter
The Heart Research Institute, 145 Missenden Road, Camperdown, Sydney, NSW 2050, Australia
Atheroscler Suppl 6:15-20. 2005..Additional protection from atherosclerosis may be provided by novel therapies that aim to increase plasma levels and activity of HDLs... - HDL: a recipe for longevityPhilip Barter
The Heart Research Institute, 145 Missenden Road, Camperdown, Sydney, NSW 2050, Australia
Atheroscler Suppl 5:25-31. 2004..As data accumulate on the protective role of HDLs, there is growing support for interventions that act to raise HDL-C concentrations... - Antiinflammatory properties of HDLPhilip J Barter
The Heart Research Institute, 145 Missenden Rd, Camperdown, Sydney 2050, Australia
Circ Res 95:764-72. 2004..These antioxidant and antiinflammatory properties of HDL may be as important as its cholesterol efflux function in terms of protecting against the development of atherosclerosis... - Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular diseasePhilip J Barter
The Heart Research Institute, Camperdown, Sydney, Australia
J Am Coll Cardiol 47:492-9. 2006..Larger, long-term, randomized, clinical end point trials are required to determine whether the beneficial effects of CETP inhibitors on lipoprotein metabolism can translate into reductions in cardiovascular events... - Metabolic abnormalities: high-density lipoproteinsPhilip Barter
The Heart Research Institute, 145 Missenden Road, Camperdown, Sydney NSW 2050, Australia
Endocrinol Metab Clin North Am 33:393-403. 2004..The consequences of a low HDL concentration in this syndrome are addressed before the article concludes with a discussion of whether low HDL in the metabolic syndrome should be a therapeutic target... - Managing diabetic dyslipidaemia--beyond LDL-C:HDL-C and triglyceridesPhilip Barter
The Heart Research Institute, 145 Missenden Road, Camperdown, Sydney, NSW 2050, Australia
Atheroscler Suppl 7:17-21. 2006.... - Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosisPhilip J Barter
Hanson Institute and the Department of Cardiology, Royal Adelaide Hospital, Adelaide, Australia
Arterioscler Thromb Vasc Biol 23:160-7. 2003..Thus, it seems important and timely to test the hypothesis in randomized trials of humans that pharmacological inhibition of CETP retards the development of atherosclerosis... 
The 5A apolipoprotein A-I mimetic peptide displays antiinflammatory and antioxidant properties in vivo and in vitroFatiha Tabet
Lipid Research Group, Heart Research Institute, Sydney, New South Wales, Australia
Arterioscler Thromb Vasc Biol 30:246-52. 2010..CONCLUSIONS: Like apoA-I, the 5A peptide inhibits acute inflammation and oxidative stress in rabbit carotids and HCAECs. In vitro, the 5A peptide exerts these beneficial effects through interaction with ABCA1...- Nonenzymatic glycation impairs the antiinflammatory properties of apolipoprotein A-IEstelle Nobecourt
Lipid Research Group, The Heart Research Institute, Sydney, New South Wales, Australia
Arterioscler Thromb Vasc Biol 30:766-72. 2010..The goal of this study was to investigate the effects of nonenzymatic glycation on the antiinflammatory properties of apolipoprotein (apo) A-I... - Acute hypertriglyceridaemia in humans increases the triglyceride content and decreases the anti-inflammatory capacity of high density lipoproteinsSanjay Patel
The Heart Research Institute, Sydney, Australia
Atherosclerosis 204:424-8. 2009..In this study, the influence of acute hypertriglyceridaemia on the composition and anti-inflammatory properties of HDL was investigated... - The apolipoprotein A-I mimetic peptide ETC-642 exhibits anti-inflammatory properties that are comparable to high density lipoproteinsBelinda A Di Bartolo
Lipid Research Group, Heart Research Institute, Sydney, Australia
Atherosclerosis 217:395-400. 2011..This study aimed to compare the anti-inflammatory effects of ETC-642, a new apoA-I mimetic peptide, with discoidal reconstituted HDL (rHDL)... - High-density lipoproteins suppress chemokines and chemokine receptors in vitro and in vivoChristina A Bursill
Heart Research Institute, 7 Eliza St, Sydney, New South Wales 2042, Australia
Arterioscler Thromb Vasc Biol 30:1773-8. 2010..To investigate whether high-density lipoproteins (HDLs) suppress chemokine (CCL2, CCL5, and CX(3)CL1) and chemokine receptor (CCR2 and CX(3)CR1) expression, a mechanism for the atheroprotective properties of HDLs... - Effects of high-density lipoproteins on pancreatic beta-cell insulin secretionMichelle A Fryirs
The Heart Research Institute, Sydney, New South Wales, Australia
Arterioscler Thromb Vasc Biol 30:1642-8. 2010..Given the current interest in therapeutic interventions that raise HDLs levels, this study investigates the effects of HDLs on insulin secretion from beta-cells... - Low dose apolipoprotein A-I rescues carotid arteries from inflammation in vivoRajesh Puranik
The Heart Research Institute, Lipid Research Group 145, Missenden Road, Sydney, NSW 2050, Australia
Atherosclerosis 196:240-7. 2008..These findings have potential implications for treating acute vascular inflammation in conditions such as acute coronary and stroke syndromes... - Formation and metabolism of prebeta-migrating, lipid-poor apolipoprotein A-IKerry Anne Rye
Heart Research Institute, Camperdown, Sydney, NSW, Australia
Arterioscler Thromb Vasc Biol 24:421-8. 2004..This review describes current knowledge regarding the formation, metabolism, and regulation of monomolecular, lipid-free/lipid-poor apoA-I in plasma... - Lipid-free apolipoprotein A-I and discoidal reconstituted high-density lipoproteins differentially inhibit glucose-induced oxidative stress in human macrophagesFatiha Tabet
Lipid Research Group, The Heart Research Institute, 7 Eliza Street, Sydney, New South Wales 2042, Australia
Arterioscler Thromb Vasc Biol 31:1192-200. 2011.... - Formation of high density lipoproteins containing both apolipoprotein A-I and A-II in the rabbitNeil J Hime
Lipid Research Group, The Heart Research Institute, Camperdown, Sydney, New South Wales 2050, Australia
J Lipid Res 47:115-22. 2006..We conclude that, irrespective of the form in which apoA-II enters the plasma, it is rapidly incorporated into spherical HDLs that also contain apoA-I to form (A-I/A-II)HDL... - Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbitsStephen J Nicholls
Heart Research Institute, Sydney, Australia
Circulation 111:1543-50. 2005..CONCLUSIONS: Infusion of rHDL, apoA-I, and phospholipid-SUVs inhibits the early pro-oxidant and proinflammatory changes induced by a periarterial collar in normocholesterolemic rabbits... - N-Glycosylation regulates endothelial lipase-mediated phospholipid hydrolysis in apoE- and apoA-I-containing high density lipoproteinsDanielle Skropeta
Lipid Research Group, Heart Research Institute, Camperdown, New South Wales 2050, Australia
J Lipid Res 48:2047-57. 2007..These data show that individual N-linked glycans have unique and important effects on the phospholipase activity and substrate specificity of EL... - Remodeling of apolipoprotein E-containing spherical reconstituted high density lipoproteins by phospholipid transfer proteinNongnuch Settasatian
Lipid Research Group, Heart Research Institute, Sydney, New South Wales 2050, Australia
J Lipid Res 49:115-26. 2008..It is concluded that apoE enhances the capacity of PLTP to remodel HDL but reduces the ability of HDL to participate in PLTP-mediated phospholipid transfers... - Regulation of reconstituted high density lipoprotein structure and remodeling by apolipoprotein EKerry Anne Rye
Lipid Research Group, The Heart Research Institute, Camperdown, Sydney, New South Wales, Australia
J Lipid Res 47:1025-36. 2006.... - Apolipoprotein A-II inhibits high density lipoprotein remodeling and lipid-poor apolipoprotein A-I formationKerry Anne Rye
Lipid Research Laboratory, Hanson Institute, Adelaide, South Australia 5000, Australia
J Biol Chem 278:22530-6. 2003.... - Impact of short-term administration of high-density lipoproteins and atorvastatin on atherosclerosis in rabbitsStephen J Nicholls
The Heart Research Institute, Sydney, Australia
Arterioscler Thromb Vasc Biol 25:2416-21. 2005..CONCLUSIONS: Infusing small amounts of HDL rapidly reduces lesion size and is comparable to atorvastatin in promoting a stable plaque phenotype... - Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trialPhilip J Barter
The Heart Research Institute, Sydney, Australia
Circulation 124:555-62. 2011..We now investigate effects on glucose homeostasis of inhibiting cholesteryl ester transfer protein with torcetrapib... - Anti-inflammatory effects of apolipoprotein A-I in the rabbitSanjay Patel
Lipid Research Group, The Heart Research Institute, Sydney, NSW 2042, Australia
Atherosclerosis 212:392-7. 2010..The present study asks if this benefit is related to an improved anti-inflammatory capacity of the high-density lipoprotein (HDL) fraction, or to increased arterial expression of genes that inhibit inflammation... - New insights into the role of HDL as an anti-inflammatory agent in the prevention of cardiovascular diseasePhilip J Barter
The Heart Research Institute, 114 Pyrmont Bridge Road, Camperdown, Sydney 2050, Australia
Curr Cardiol Rep 9:493-8. 2007..These results have potentially important clinical implications in regard to managing the acute vascular inflammation states that accompany acute coronary syndrome and acute ischemic stroke... - High-density lipoproteins as therapeutic targetsStephen J Nicholls
The Heart Research Institute, Sydney, Australia
Curr Opin Lipidol 16:345-9. 2005.... - Apolipoprotein E enhances hepatic lipase-mediated hydrolysis of reconstituted high-density lipoprotein phospholipid and triacylglycerol in an isoform-dependent mannerNeil J Hime
Lipid Research Group, The Heart Research Institute, Camperdown, Sydney, New South Wales, Australia
Biochemistry 43:12306-14. 2004..These results show that apoE increases the rate of HL-mediated phospholipid and triacylglycerol hydrolysis in rHDL and that this influence is isoform dependent... - High-density lipoproteins neutralize C-reactive protein proinflammatory activityCarol Wadham
Division of Human Immunology, Hanson Institute, Institute of Medical and Veterinary Science, Adelaide, South Australia, Australia
Circulation 109:2116-22. 2004..CONCLUSIONS: The CRP-induced upregulation of inflammatory adhesion molecules in HUVECs was completely prevented by HDL via their oxidized phospholipid components... - Effects of torcetrapib in patients at high risk for coronary eventsPhilip J Barter
Heart Research Institute, Camperdown, Sydney, NSW, Australia
N Engl J Med 357:2109-22. 2007..We investigated whether torcetrapib, a potent CETP inhibitor, might reduce major cardiovascular events. The trial was terminated prematurely because of an increased risk of death and cardiac events in patients receiving torcetrapib... - Inhibition of rupture of established atherosclerotic plaques by treatment with apolipoprotein A-IGerrit J Reimers
The Heart Research Institute, 7 Eliza Street, Newtown NSW 2042, Australia
Cardiovasc Res 91:37-44. 2011..We investigated the effect of treatment with human apolipoprotein A-I (apoA-I), the principal protein of HDL, on plaque disruption in an animal model... - Consumption of saturated fat impairs the anti-inflammatory properties of high-density lipoproteins and endothelial functionStephen J Nicholls
The Heart Research Institute, Sydney, Australia
J Am Coll Cardiol 48:715-20. 2006..In contrast, the anti-inflammatory activity of HDL improves after consumption of polyunsaturated fat. These findings highlight novel mechanisms by which different dietary fatty acids may influence key atherogenic processes... - High-density lipoproteins enhance progenitor-mediated endothelium repair in miceColin Tso
Heart Research Institute, Sydney, NSW 2050, Australia
Arterioscler Thromb Vasc Biol 26:1144-9. 2006..The observation that number is further increased in apoE(-/-) mice after injection of HDL suggests a role for HDL in promoting progenitor-mediated endothelial repair... - Long-term fenofibrate therapy increases fibroblast growth factor 21 and retinol-binding protein 4 in subjects with type 2 diabetesKwok Leung Ong
Lipid Research Group, Heart Research Institute, Sydney, New South Wales 2042, Australia
J Clin Endocrinol Metab 97:4701-8. 2012.... - Niacin inhibits vascular inflammation via the induction of heme oxygenase-1Ben J Wu
Lipid Research Group, The Heart Research Institute, 7 Eliza St, Newtown, NSW, Australia, 2042
Circulation 125:150-8. 2012..This study asks if the cardioprotective properties of niacin involve the induction of HO-1... - Cholesterol metabolism and pancreatic beta-cell functionMichelle Fryirs
Lipid Research Group, The Heart Research Institute, New South Wales, Australia
Curr Opin Lipidol 20:159-64. 2009..This review summarizes recent advances in understanding the relationship between beta-cell cholesterol metabolism and beta-cell function... - Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome?Philip J Barter
The Heart Research Institute, Sydney, Australia 2050
Arterioscler Thromb Vasc Biol 28:39-46. 2008..It remains to be determined whether the combination of a fibrate plus statin reduces the risk beyond that achieved with a statin alone... - Arthritis: its prevalence, risk factors, and association with cardiovascular diseases in the United States, 1999 to 2008Kwok Leung Ong
Lipid Research Group, Heart Research Institute, Sydney, New South Wales, Australia
Ann Epidemiol 23:80-6. 2013..However, there are limited epidemiologic studies on arthritis in a national survey study. We therefore investigated the prevalence of self-reported arthritis and its association with CVDs... - Predictive value of different HDL particles for the protection against or risk of coronary heart diseaseKerry Anne Rye
Lipid Research Group, The Heart Research Institute, Sydney, NSW, Australia
Biochim Biophys Acta 1821:473-80. 2012..This article is part of a Special Issue entitled Advances in High Density Lipoprotein Formation and Metabolism: A Tribute to John F. Oram (1945-2010)... - Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER DatabasePhilip J Barter
Heart Research Institute, Sydney, Australia
J Lipid Res 51:1546-53. 2010..The HDL-C increase achieved by all three statins was independent of LDL-C decrease. However, baseline HDL-C and TGs and the presence of diabetes were predictors of statin-induced increases in HDL-C... - Is it appropriate to make statins available over the counter? The argument against the appropriateness of over-the-counter statinsPhilip J Barter
The Heart Research Institute and the Department of Medicine, University of Sydney, Australia
Circulation 114:1315-20; discussion 1320. 2006 - Serum insulin and inflammatory markers in overweight individuals with and without dyslipidemiaPhilip Barter
The Heart Research Institute, Camperdown, New South Wales, Australia
J Clin Endocrinol Metab 92:2041-5. 2007..The worldwide epidemic of overweight and obesity is setting the scene for a new wave of premature cardiovascular disease... - HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular eventsPhilip Barter
Heart Research Institute, Sydney, Australia
N Engl J Med 357:1301-10. 2007..High-density lipoprotein (HDL) cholesterol levels are a strong inverse predictor of cardiovascular events. However, it is not clear whether this association is maintained at very low levels of low-density lipoprotein (LDL) cholesterol... - Are we lowering LDL cholesterol sufficiently?Philip Barter
The Heart Research Institute, Sydney, NSW, Australia
Nat Clin Pract Cardiovasc Med 3:290-1. 2006 - Lessons learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trialPhilip Barter
The Heart Research Institute, 7 Eliza Street, Newtown, Sydney, New South Wales, Australia 2042
Am J Cardiol 104:10E-5E. 2009..The potential of CETP inhibition to reduce cardiovascular risk will be determined by the outcome of ongoing clinical trials with CETP inhibitors that do not share the off-target effects of torcetrapib... - High-density lipoproteins inhibit vascular endothelial inflammation by increasing 3β-hydroxysteroid-Δ24 reductase expression and inducing heme oxygenase-1Ben J Wu
Lipid Research Group, The Heart Research Institute, 7 Eliza St, Newtown, Sydney, New South Wales 2042, Australia
Circ Res 112:278-88. 2013..Lipid-free apolipoprotein (apo) A-I and discoidal reconstituted high-density lipoproteins (rHDL) containing apoA-I, (A-I)rHDL, inhibit vascular inflammation by increasing 3β-hydroxysteroid-Δ24 reductase (DHCR24) expression... - Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular riskPhilip J Barter
The Heart Research Institute, Sydney, New South Wales, 2042, Australia
J Lipid Res 53:1755-66. 2012.... - Relationship between atorvastatin dose and the harm caused by torcetrapibPhilip J Barter
The Heart Research Institute, Sydney, Australia
J Lipid Res 53:2436-42. 2012..The harm could not be explained by torcetrapib-induced changes in lipid levels, blood pressure, or electrolytes. It is conceivable that higher doses of atorvastatin protected against the harm caused by torcetrapib... - Association of lower total bilirubin level with statin usage: the United States National Health and Nutrition Examination Survey 1999-2008Kwok Leung Ong
Lipid Research Group, Heart Research Institute, 7 Eliza Street, Newtown, Sydney, NSW 2042, Australia
Atherosclerosis 219:728-33. 2011..As statins can stimulate heme oxygenase-1 (HO-1), which increases bilirubin production, we investigated whether statins in routine use increase total bilirubin levels in subjects at high cardiovascular risk... - Metabolism of apoA-I as lipid-free protein or as component of discoidal and spherical reconstituted HDLs: studies in wild-type and hepatic lipase transgenic rabbitsPatrick Kee
University Department of Medicine, Royal Adelaide Hospital, Adelaide, Australia
Arterioscler Thromb Vasc Biol 22:1912-7. 2002.... - The metabolism and anti-atherogenic properties of HDLKerry Anne Rye
Lipid Research Group, The Heart Research Institute, Sydney, NSW, Australia
J Lipid Res 50:S195-200. 2009..This review documents what is known about the relationship between the metabolism and function of HDL subpopulations and how this affects their cardioprotective properties... - Effectiveness of combined statin plus omega-3 fatty acid therapy for mixed dyslipidemiaPhilip Barter
Heart Research Institute, Camperdown, Sydney, New South Wales, Australia
Am J Cardiol 102:1040-5. 2008..In conclusion, several classes of drugs, including omega-3 fatty acids, can be used in combination with statins to achieve more global improvements in lipid profiles... - High density lipoproteins (HDLs) and atherosclerosis; the unanswered questionsPhilip Barter
Cardiovascular Investigation Unit, Royal Adelaide Hospital, North Terrace, Adelaide, SA 5000, Australia
Atherosclerosis 168:195-211. 2003..This review summarises what is known and highlights what we still need to know... - Evidence that hepatic lipase and endothelial lipase have different substrate specificities for high-density lipoprotein phospholipidsMyNgan Duong
Department of Medicine, University of Adelaide, North Terrace, Australia
Biochemistry 42:13778-85. 2003..These results establish that EL and HL have different substrate specificities for rHDL phospholipids and that their interactions with the rHDL surface are regulated by phospholipids... - Evidence that phospholipids play a key role in pre-beta apoA-I formation and high-density lipoprotein remodelingKerry Anne Rye
Lipid Research Laboratory, Hanson Institute, Adelaide, South Australia, Australia 5000
Biochemistry 41:12538-45. 2002..In conclusion, these results show that phospholipids play a key role in the CETP-mediated remodeling of rHDL and pre-beta apoA-I formation... - Antiinflammatory actions of HDL: a new insightKerry-Anne Rye
Arterioscler Thromb Vasc Biol 28:1890-1. 2008 - Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) studyHerbert Schuster
Humboldt University, Berlin, Germany
Am Heart J 147:705-13. 2004.... - Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemiaJohn J P Kastelein
Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
N Engl J Med 356:1620-30. 2007..Torcetrapib, an inhibitor of cholesteryl ester transfer protein, may reduce atherosclerotic vascular disease by increasing levels of high-density lipoprotein (HDL) cholesterol... - Coronary plaque regression: role of low density lipoprotein-apheresisPhilip J Barter
J Am Coll Cardiol 40:228-30. 2002 - Relation between atherogenic dyslipidemia and the Adult Treatment Program-III definition of metabolic syndrome (Genetic Epidemiology of Metabolic Syndrome Project)Diego F Wyszynski
Department of Medicine (Genetics Program, Boston University School of Medicine, Boston, MA, USA
Am J Cardiol 95:194-8. 2005..In subjects aged <35 years, atherogenic dyslipidemia frequently occurs in the absence of other metabolic syndrome risk factors... - Multiple QTLs influencing triglyceride and HDL and total cholesterol levels identified in families with atherogenic dyslipidemiaYi Yu
Department of Medicine (Genetics Program, Boston University School of Medicine, Boston, MA, USA
J Lipid Res 46:2202-13. 2005..These data also indicate that a large proportion of the variance of TG levels in the Turkish population is explained by the interaction of multiple genetic loci... - Identification and characterization of two non-secreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South AfricaVivienne M Homer
Canterbury Health Laboratories, 8001 Christchurch, New Zealand
Atherosclerosis 196:659-66. 2008..Our study therefore indicates that PCSK9 mediated inhibition of the LDLR does not require PCSK9 autocatalytic cleavage or secretion, suggesting that PCSK9 may also function intracellularly...